What is HC Wainwright’s Forecast for BLSM Q2 Earnings?

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) – Equities researchers at HC Wainwright issued their Q2 2026 earnings estimates for shares of BlossomHill Therapeutics in a research report issued to clients and investors on Tuesday, September 1st. HC Wainwright analyst R. Burns forecasts that the company will post earnings per share of ($0.90) for the quarter. HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. HC Wainwright also issued estimates for BlossomHill Therapeutics’ Q3 2026 earnings at ($0.92) EPS, Q4 2026 earnings at ($0.90) EPS, FY2026 earnings at ($3.71) EPS, Q1 2027 earnings at ($0.86) EPS, Q2 2027 earnings at ($0.77) EPS, Q3 2027 earnings at ($0.69) EPS, Q4 2027 earnings at ($0.69) EPS and FY2027 earnings at ($2.99) EPS.

Several other research analysts have also issued reports on BLSM. JPMorgan Chase & Co. started coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They set an “overweight” rating and a $28.00 price target for the company. Leerink Partners started coverage on BlossomHill Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $36.00 price target on the stock. Lifesci Capital assumed coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They set an “outperform” rating and a $32.00 price objective for the company. Guggenheim assumed coverage on BlossomHill Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $30.00 price target for the company. Finally, Wall Street Zen upgraded shares of BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $32.20.

BlossomHill Therapeutics Trading Up 2.1%

Shares of NASDAQ:BLSM opened at $19.38 on Thursday. BlossomHill Therapeutics has a 12-month low of $15.25 and a 12-month high of $20.61.

Insider Buying and Selling at BlossomHill Therapeutics

In other BlossomHill Therapeutics news, Director Orbimed Advisors Llc bought 625,000 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Following the purchase, the director directly owned 2,714,279 shares of the company’s stock, valued at $43,428,464. The trade was a 29.91% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bihua Chen acquired 312,500 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the transaction, the director owned 3,614,034 shares of the company’s stock, valued at $57,824,544. The trade was a 9.47% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 1,573,900 shares of company stock valued at $25,181,900 over the last 90 days.

Trending Headlines about BlossomHill Therapeutics

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: Several firms recently initiated coverage with bullish ratings and price targets above the current trading level: Leerink Partners rated the shares “Outperform” with a $36 target, HC Wainwright rated them “Buy” with a $35 target, Guggenheim rated them “Buy” with a $30 target, Lifesci Capital rated them “Outperform” with a $32 target, and JPMorgan assigned an “Overweight” rating with a $28 target. The concentration of favorable ratings provides a positive sentiment catalyst for BLSM. Lifesci Capital Initiates Coverage JPMorgan Coverage Initiation
• Positive Sentiment: HC Wainwright’s reiterated “Buy” rating and $35 price objective imply substantial appreciation potential. Its forecasts also show expected losses narrowing from $3.71 per share in fiscal 2026 to $2.99 per share in fiscal 2027, with quarterly losses projected to improve from roughly $0.90–$0.92 to $0.69–$0.86. This improving earnings trajectory could reinforce the bullish case, although the company remains unprofitable. HC Wainwright Estimates and Rating
• Neutral Sentiment: BlossomHill announced upcoming presentations at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright Global Investment Conference. The events may give investors additional information about its cancer programs, but the announcement itself does not provide new clinical results. BlossomHill Conference Presentations
• Neutral Sentiment: The company also plans to present updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643, its OMNI-EGFR inhibitor, in EGFR-mutant non-small-cell lung cancer. Investors may view forthcoming data as an important pipeline catalyst, while clinical-stage and loss-making status remain key risks.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.